Cencora, Inc. $COR Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group boosted its holdings in Cencora, Inc. (NYSE:COR) by 19.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 278,883 shares of the company’s stock after acquiring an additional 45,666 shares during the quarter. Schroder Investment Management Group’s holdings in Cencora were worth $83,623,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC boosted its position in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Costello Asset Management INC bought a new stake in shares of Cencora during the first quarter valued at about $28,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Cencora in the second quarter worth about $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in Cencora in the 2nd quarter valued at about $61,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.1%

Cencora stock opened at $368.93 on Friday. The firm has a market cap of $71.53 billion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The firm’s 50 day moving average price is $335.71 and its two-hundred day moving average price is $307.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 30.19%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on COR. Wells Fargo & Company boosted their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Mizuho raised their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Robert W. Baird upped their target price on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Evercore ISI set a $400.00 price target on Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, UBS Group boosted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,640 shares of company stock worth $14,099,338 in the last three months. 10.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.